Rizvi N, Cho B, Reinmuth N, Lee K, Luft A, Ahn M, Papadimitrakopoulou V, Heymach J, Scheuring U, Higgs B, Ye J, Kuziora M, Wu S, Liu F, Si H, Peters S. OA04.07 Mutations Associated with Sensitivity or Resistance to Immunotherapy in mNSCLC: Analysis from the MYSTIC Trial. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.428] [Citation(s) in RCA: 17] [Impact Index Per Article: 3.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]

Ahn M, Liu Y, Improta T, Marcovitz M, Dipiazza K, Lanasa M. P2.01-18 ORION: Durvalumab+Olaparib Versus Durvalumab Alone as Maintenance Therapy in Stage IV Non-Small Cell Lung Cancer (NSCLC). J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.1362] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]

Ahn M, Park S, Hong S, Park J, Park M, Jung H, Sun J, Lee S, Ahn J, Park K. MA21.10 Phase II Study of 160mg of Osimertinib in EGFR T790M Positive NSCLC with Brain or Leptomeningeal Metastases Who Progressed on Prior EGFR TKI. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.680] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.2] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]

Mazieres J, Ahn M, Chouaid C, Kron A, Wolf J, Goyal R, Davis K, Perrinjaquet M, Pham T, Knoll S. P1.16-46 Genetic Testing Patterns, Treatment Characteristics, and Overall Survival in ALK-Positive Metastatic NSCLC Patients Treated with Ceritinib. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.1272] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]

Kim Y, Kim C, Lee S, Lee H, Kim H, Kim K, Sun J, Ahn J, Ahn M, Park K. OA14.07 Clinical and Genetic Characterization of Hyperprogression Based on Volumetry in Advanced NSCLC Treated with Immunotherapy. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.488] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/01/2022]

Ku B, Jung H, Sun J, Lee S, Ahn J, Park K, Ahn M. P2.09-07 Multiple Immunohistochemistry of Non-Small Cell Lung Cancers Reveals Distinct Immune Context. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.1656] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]

John T, Taylor A, Wang H, Cripps D, Eichinger C, Freeman C, Ahn M. P1.01-136 Uncommon EGFR Mutations in Non-Small Cell Lung Cancer: A Systematic Literature Review of Prevalence and Clinical Outcomes. J Thorac Oncol 2019. [DOI: 10.1016/j.jtho.2019.08.851] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/25/2022]

Tang J, Solis D, Siprashvili Z, Whitehead N, Schu M, Fang F, Erickson S, Ritchey M, Colao M, Tyrpien M, Rouhandeh C, Spratt K, Ahn M. 271 From clinical to genotypic modeling: Recessive Dystrophic Epidermolysis Bullosa (RDEB). J Invest Dermatol 2019. [DOI: 10.1016/j.jid.2019.03.347] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]

Kim D, Huber R, Ahn M, Langer C, Tiseo M, West H, Groen H, Reckamp K, Hochmair M, Leighl N, Hansen K, Gettinger S, Paz-Ares Rodriguez L, Kim E, Smit E, Kim S, Reichmann W, Kerstein D, Camidge D. Brigatinib in crizotinib-refractory ALK+ non-small cell lung cancer (NSCLC): efficacy updates and exploratory analysis of target lesion response by baseline brain lesion status in the ALTA Trial. Lung Cancer 2019. [DOI: 10.1016/s0169-5002(19)30120-5] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/27/2022]

Ou S, Cho B, Kim D, Drilon A, Lee J, Lin J, Zhu V, Ahn M, Camidge D, Stopatschinskaja SS, Liu J, Cui J, Hyman D, Doebele R, Shaw A. OA09 Preliminary Clinical Activity of Repotrectinib (TPX-0005) in Advanced ROS1 Fusion-Positive Non-Small Cell Lung Cancer. J Thorac Oncol 2018. [DOI: 10.1016/j.jtho.2018.10.019] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/27/2022]

Cho J, Hyeon J, Choi Y, Sun J, Lee S, Ahn J, Park K, Ahn M. P3.01-18 Comparison of PD-L1 Immunohistochemical Assays and Clinical Response to Anti PD-1 Checkpoint Inhibitors in Patients with Lung Cancer. J Thorac Oncol 2018. [DOI: 10.1016/j.jtho.2018.08.1578] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]

Lin J, Kim D, Drilon A, Doebele R, Lee J, Zhu V, Ahn M, Lim J, Stopatschinskaja S, Cui J, Hyman D, Camidge R, Ou S, Shaw A, Cho B. OA02.02 Safety and Preliminary Clinical Activity of Ropotrectinib (TPX-0005), a ROS1/TRK/ALK Inhibitor, in Advanced ROS1 Fusion-Positive NSCLC. J Thorac Oncol 2018. [DOI: 10.1016/j.jtho.2018.08.240] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]

Kim H, Ahn Y, Kim J, Pyo H, Noh J, Sun J, Ahn J, Ahn M, Park K, Choi Y, Kim J, Zo J, Shim Y, Han J, Hyun S, Choi J. P2.01-57 Prognostic Implication of Clinical, Imaging, and Pathologic Parameters in N2(+) Stage IIIA Lung Cancer Patients. J Thorac Oncol 2018. [DOI: 10.1016/j.jtho.2018.08.1111] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]

Doebele R, Ahn M, Siena S, Drilon A, Krebs M, Lin C, De Braud F, John T, Tan D, Seto T, Dziadziuszko R, Arkenau H, Barlesi F, Rolfo C, Wolf J, Chow-Maneval E, Multani P, Cui N, Riehl T, Cho B. OA02.01 Efficacy and Safety of Entrectinib in Locally Advanced or Metastatic ROS1 Fusion-Positive Non-Small Cell Lung Cancer (NSCLC). J Thorac Oncol 2018. [DOI: 10.1016/j.jtho.2018.08.239] [Citation(s) in RCA: 36] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]

Park K, Ahn M, Lee S, Kim H, Hong M, Millington D, Curtis M, Triantos S, Chaplan S, Haddish-Berhane N, Knoblauch R, Aguilar Z, Laquerre S, Lorenzi M, Cho B. OA10.06 A First-in-Human Phase 1 Trial of the EGFR-cMET Bispecific Antibody JNJ-61186372 in Patients with Advanced Non-Small Cell Lung Cancer (NSCLC). J Thorac Oncol 2018. [DOI: 10.1016/j.jtho.2018.08.292] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]

Bak S, Park H, Sohn I, Lee H, Lee S, Ahn M. P2.01-10 Prognostic Impact of Longitudinal Monitoring of Radiomic Features in Patients with Advanced Non-Small Cell Lung Cancer. J Thorac Oncol 2018. [DOI: 10.1016/j.jtho.2018.08.1064] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]

Koh J, Lee K, Kim B, Kim M, Cho H, Bae Y, Ku B, Sun J, Lee S, Ahn J, Park K, Ahn M. P1.04-03 Suppressive Immune Cell Profiling in Patients with Non-Small Cell Lung Cancer. J Thorac Oncol 2018. [DOI: 10.1016/j.jtho.2018.08.718] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]

Ahn M. MS28.02 Combination IO+IO. J Thorac Oncol 2018. [DOI: 10.1016/j.jtho.2018.08.194] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]

Shin S, Lee S, Choi Y, Cho J, Kim H, Choi Y, Han J, Sun J, Ahn J, Ahn M, Park K, Zo J, Shim Y, Kim J. P3.16-41 Postoperative Pembrolizumab for the Patients with Pathologic Stage I Adenocarcinoma with Solid or Micropapillary Pattern. J Thorac Oncol 2018. [DOI: 10.1016/j.jtho.2018.08.1948] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/28/2022]

Ahn M. MS 13.05 Targeted Therapy for EGFR Positive Mutant NSCLC with CNS Metastasis. J Thorac Oncol 2017. [DOI: 10.1016/j.jtho.2017.09.247] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]

Lee H, Lee H, Sun J, Lee S, Kim Y, Park S, Ahn J, Park K, Ahn M. P3.01-029 Transient Asymptomatic Pulmonary Opacities (TAPOs) during Osimertinib Treatment and Its Clinical Implication. J Thorac Oncol 2017. [DOI: 10.1016/j.jtho.2017.09.1470] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]

Ahn M, Han J, Sequist L, Cho B, Lee J, Kim S, Su W, Tsai C, Yang J, Yu H, Horn L, Lee K, Haddad V, Frigault M, Ahmed G, Yang L, Ghiorghiu D, Oxnard G. OA 09.03 TATTON Ph Ib Expansion Cohort: Osimertinib plus Savolitinib for Pts with EGFR-Mutant MET-Amplified NSCLC after Progression on Prior EGFR-TKI. J Thorac Oncol 2017. [DOI: 10.1016/j.jtho.2017.09.377] [Citation(s) in RCA: 14] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]

Kim H, Shin S, Cho J, Choi Y, Zo J, Shim Y, Park K, Ahn M, Ahn J, Lee S, Sun J, Ahn Y, Pyo H, Noh J, Han J, Kim J. P3.08-006 Treatment Response and Survival Outcomes Are Associated with Histologic Type in Non-Small Cell Lung Cancer Treated with Trimodal Treatment. J Thorac Oncol 2017. [DOI: 10.1016/j.jtho.2017.09.1710] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]

Sun J, Lee K, Kim B, Kim H, Min Y, Yi S, Yun H, Lee S, Ahn J, Park K, Ahn M. OA 08.07 Pazopanib Maintenance for Extensive Disease Small Cell Lung Cancer: a Randomized, Placebo-Controlled Phase II study (KCSG-LU12-07). J Thorac Oncol 2017. [DOI: 10.1016/j.jtho.2017.09.374] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]

Shin S, Cho J, Kim H, Choi Y, Kim J, Zo J, Park K, Ahn M, Ahn J, Sun J, Lee S, Shim Y. P3.01-082 Surgical Rebiopsy in Advanced Non-Small Cell Lung Cancer Resistant to Previous Chemotherapy. J Thorac Oncol 2017. [DOI: 10.1016/j.jtho.2017.09.1523] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]